low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by clinical milestones rather than economic conditions. However, capital markets access for financing is cyclical, with biotech IPO/follow-on windows tightening during recessions. Patient enrollment can be marginally affected by healthcare utilization patterns during severe downturns.

Rising interest rates negatively impact valuation through higher discount rates applied to distant cash flows (8-10+ years for potential commercialization). Higher rates also reduce appetite for speculative growth assets and increase competition from risk-free alternatives. Amylyx holds significant cash balances that benefit from higher short-term rates (estimated $170M earning 4-5% vs 0% in 2021), partially offsetting valuation compression. Debt financing is minimal (0.02 D/E) so direct interest expense impact is negligible.

momentum/speculative - Stock exhibits extreme volatility (296.9% 1-year return, 76.6% 6-month) attracting biotech specialists, event-driven traders, and retail momentum players betting on clinical catalysts. The 1.1% 3-month return vs 76.6% 6-month suggests recent consolidation after major move. Not suitable for value investors given negative earnings and pre-revenue status. No dividend. Institutional ownership likely concentrated among specialized healthcare funds willing to accept binary risk/reward.